Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research

Executive Summary

Pharmaceutical companies would be required to pay a "return on investment fee" from profits on drugs that benefited from federal research funding under a Medicare drug benefit proposal outlined May 26 by Rep. Thomas (R-Calif.) and Sen. Wyden (D-Ore.).

You may also be interested in...



DTC Restrictions Under Consideration For House Medicare Rx Bill

House Ways & Means Committee leadership is considering adding direct-to-consumer advertising restrictions to Medicare prescription drug benefit legislation.

DTC Restrictions Under Consideration For House Medicare Rx Bill

House Ways & Means Committee leadership is considering adding direct-to-consumer advertising restrictions to Medicare prescription drug benefit legislation.

NIH Royalty Plan Due March 31 Under Wyden Amendment To Funding Bill

The National Institutes of Health would be directed to develop a plan to ensure a "reasonable rate of return" on taxpayer funded research under an amendment to the Senate Labor/HHS appropriations bill.

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel